LAG3 as a marker of immune activation in esophageal squamous carcinoma treated with concurrent chemoradiotherapy
Concurrent chemoradiotherapy without combined immunotherapy inhibited tumor-infiltrating T cells to a certain extent, and elevated immune checkpoint LAG3 was closely associated with immune activation in the ESCC tumor microenvironment.
Authors
- Fangdong Zhao
- Yuanyuan Rui (ORCID: https://orcid.org/0009-0006-3017-648X)
- Ziyang Zhou (ORCID: https://orcid.org/0000-0003-0154-6948)
- Y. Zhang (ORCID: https://orcid.org/0000-0002-6485-4844)
- Hui Huang (ORCID: https://orcid.org/0000-0002-2279-8418)
- Zhen Peng (ORCID: https://orcid.org/0000-0001-9352-9613)
- Qingsong Pang (ORCID: https://orcid.org/0000-0002-3576-6909)
- Xi Chen (ORCID: https://orcid.org/0009-0000-6053-3851)
- Ping Wang (ORCID: https://orcid.org/0000-0001-6474-2722)
- Jiarui Zhang (ORCID: https://orcid.org/0009-0009-2549-8742)
- Fang Fang (ORCID: https://orcid.org/0000-0002-5272-302X)
- Jiacheng Li (ORCID: https://orcid.org/0000-0001-6110-7774)
- Fanhao Kong
- Gang Zhao (ORCID: https://orcid.org/0000-0002-1308-4915)
- Tian Zhang (ORCID: https://orcid.org/0000-0002-0538-1071)
- Zhoubo Guo (ORCID: https://orcid.org/0009-0002-3539-1278)
- Jun Wang (ORCID: https://orcid.org/0000-0003-0376-6071)
- Wencheng Zhang
Institutions
- Hebei Medical University (CN)
- Chifeng University (CN)
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Fourth Hospital of Hebei Medical University (CN)
- Chifeng Municipal Hospital (CN)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2025-05-24
- DOI
- https://doi.org/10.1007/s00262-025-04076-2
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Inner Mongolia
- Tianjin Medical University